A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era

Abstract

The coronavirus disease 2019 (COVID-19) represents a global concern of public health caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its clinical manifestations are characterized by a heterogeneous group of symptoms and pictures (ranging from asymptomatic to lethal courses). The prevalence of conjunctivitis in patients with COVID-19 is at present controversial. Although it has been reported that only 0.9% developed signs of conjunctivitis, other report indicates that up to 31.6% of hospitalized patients had conjunctivitis. Considering the widespread use of topical ophthalmic medications (e.g., eye drops) by the general population, for various reasons (e.g., artificial tears, anti-glaucoma medications, topical antibiotics, etc.), the existence of their side effects as antiviral action should be investigated in-depth because it could possibly explain the aforementioned controversial data and represent a potential antiviral treatment for SARS-CoV-2 replication/diffusion on the ocular surface. Here, we discuss and elucidate the antiviral side effect of many eye drops and ophthalmic ointments commonly used for others purposes, thus showing that these secondary effects (not to be confused with the ‘adverse effects’) might be of primary importance in a number of viral infections (e.g., those for which there is no validated treatment protocol), according to a drug repurposing approach. Some active ingredients or excipients described here have activity against other types of viruses, thus suggesting potential broad-spectrum applications.

Estimation of case-fatality rate in COVID-19 patients with hypertension and diabetes mellitus in the New York state: a preliminary report

“…The genetic difference of angiotensin converting enzyme-2 (ACE2) may exist between different ethnicities [ 9 ] with assumptions that African Americans might be less susceptible to COVID-19. In addition, various common medicines [ 10 ] currently used in certain areas, such as hydroxychloroquine [ 11 ] could have biased the association between comorbidities and COVID-19. These findings suggest that the likelihood of getting an infection and being severe after infection should be studied separately.…”

COVID-19 and Italian Healthcare Workers From the Initial Sacrifice to the mRNA Vaccine: Pandemic Chrono-History, Epidemiological Data, Ethical Dilemmas, and Future Challenges

“…Moreover, fecal–oral ( 24 ) and ocular ( 25 ) routes might also be crucial in limiting the diffusion of the ongoing pandemic even though they are not fully understood. In the next phase, when the state of emergency became evident, the numerous previously observed variables were combined with others, such as the initially limited availability of PPE, the low rate of staff turnover (due to the shortage of collaborators), and the failure to adapt medical liability to the moment of emergency to facilitate the use of emerging therapies ( 26 , 27 ).…”

A Year of Living Dangerously: Challenges and Recommendations for Safely Performing Ophthalmic Surgery During the COVID-19 Pandemic, from Start to Finish

“… 20–22 At the moment of analysing the reason for this low percentage, one has to consider the effect of broad-spectrum antivirals in topical ophthalmic medications, a fact not reported in most publications. 23 …”